SELLAS Life Sciences Group, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report2 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
+6.52%
vs ±9.4% implied · ×0.70
shaded = implied · ▲▼ = realized
SELLAS Life Sciences has 9 disclosed suppliers and 0 disclosed customers in SEC filings.
SELLAS Life Sciences Group, Inc.
9.66
SentenceGiven the potential immunobiologic and pharmacodynamic synergy between GPS and an immune check-point inhibitor (e.g., PD-1 inhibitor), we entered into a Clinical Trial Collaboration and Supply Agreement with Merck (known as MSD outside the United States and Canada), to assess the efficacy and safety of GPS in combination with Merck's anti-PD-1 therapy pembrolizumab with exploratory long-term follow-up for OS and safety.
SentenceOn March 31, 2022, we entered into an exclusive license agreement, or the GenFleet Agreement, with GenFleet Therapeutics (Shanghai), Inc., or GenFleet, a clinical-stage biotechnology company developing cutting-edge therapeutics in oncology and immunology, that grants rights to us for the development and commercialization of SLS009, a highly selective small molecule CDK9 inhibitor, across all therapeutic and diagnostic uses worldwide, except for Greater China.
SLS 10-Kaccession 0001390478-26-000003
SentenceUnder the agreement, 119 Table of Contents the IMPACT-AML network will conduct a clinical study evaluating SLS009, enabling access to multiple European clinical sites and patients.
SLS 10-Kaccession 0001390478-26-000003
SentenceIn December 2024, we announced that the pre-specified threshold of 60 events (deaths) per the protocol had been reached, triggering the interim analysis to be conducted by the Independent Data Monitoring Committee, or IDMC.
SLS 10-Kaccession 0001390478-26-000003
SentenceOur sole CMO for GPS drug product is Lyophilization Services of New England, Inc. (PCI Pharma Services).
SLS 10-Kaccession 0001390478-26-000003
SentenceOur lead product candidate, GPS, is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the WT1 protein, which is present in 20 or more cancer types.
SLS 10-Kaccession 0001390478-26-000003
SentenceThe experiment conducted and funded by the National Institute of Health, or NIH, through through the NCI Pediatric Preclinical in Vivo Testing, or PIVOT, program, included 27 patient-derived ALL tumors from pediatric patients.
SLS 10-Kaccession 0001390478-26-000003
SentenceOur sole CMO for GPS drug substance peptides is Polypeptide Group.
SLS 10-Kaccession 0001390478-26-000003
—
—
Linked news
Expected move
Inputs8Q avg ±7.3%·×1.33·rich
straddle ±26.6%
spot 9.68exp Nov 13ATM strike 9.5ATM straddle 3.02IV 203%